The score ranges from 1 (least relevant) to 100 (most relevant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o you have a 2:1 degree or higher in business or a related subject? Get daily stock ideas top-performing Wall Street analysts. We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership. GlaxoSmithKline plc (GSK.L) pays an annual dividend of GBX 76 per share and has a dividend yield of 5.8%. These have contributed to an environment that has subjected to lower growth and high risk factors (Annual Report: GlaxoSmithKline Plc. The total articles and average engagement across all sites. GSK has high relative market share and high market growth rate along with good cash flow. This process is automatic. Dechra Pharmaceuticals PLC (DPH.L) pays an annual dividend of GBX 34 per share and has a dividend yield of 1.0%. Global Sales and Patents - GSK operates as the sixth largest pharmaceutical company with a presence in over 115 countries. The generics, CAM and brand names are the same product delivered to the customers, the only difference being name and price (Kasapi, 2011). GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review - provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. Growth in technology – Streamlining drug manufacturing is emerging as a new competitive trend with the race to develop artificial intelligence to aid in drug trials. GlaxoSmithKline plc (GSK.L) pays out 60.2% of its earnings in the form of a dividend. Potential to expand business in emerging markets. AstraZeneca PLC (AZN.L) beats GlaxoSmithKline plc (GSK.L) on 5 of the 9 factors compared between the two stocks. Alexa's competitive analysis tools help you identify competitor strengths and … GSK's brand image – After controversies surrounding the Chinese corruption scandal, market manipulation in the UK, Tax issues in the US. b) Oral Healthcare Sensodynetoothpaste and brush [Competitors- Colgate Sensitive] c) Wellness Analgesics-Crocin … AstraZeneca PLC (AZN.L) has a consensus price target of GBX 8,421.18, suggesting a potential upside of 8.32%. GlaxoSmithKline plc (GSK.L) beats Vectura Group plc (VEC.L) on 5 of the 7 factors compared between the two stocks. We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations. BMS is perceived as one of GSK's biggest rivals. View our full suite of financial calendars and market data tables, all for free. The competitors list can be found next to the search input field at the top of this page. Location of Factors The competitors list can be found next to the search input field above. 2011). (2017) GSK: continuity candidate. Scholars The number of articles mentioned in public Twitter or Reddit posts relevant to this topic. Sites that link to this site, recalculated weekly. Through these priorities they aim to deliver sustainable growth, improve long-term financial performance and reduce risks and thus adhere to their mission of improving quality of human life that enables people to do more, feel better and live longer (GlaxoSmithKline Plc., 2012b). GlaxoSmithKline Plc, 2012b. GlaxoSmithKline plc (GSK.L) pays an annual dividend of GBX 76 per share and has a dividend yield of 5.8%. identify link building and partnership opportunities to help grow your authority and traffic. This is a breakdown of current ratings and target prices for Beximco Pharmaceuticals Limited (BXP.L) and GlaxoSmithKline plc (GSK.L), as reported by MarketBeat.com. (Adapted from Annual Report: GlaxoSmithKline Plc. [])-[])), +((!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![]+[])+(!+[]+(!![])+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![]+!![])+(!+[]-(!![]))+(!+[]+(!![])+!![]+!![])+(+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![])+(+!![]))/+((!+[]+(!![])+!![]+!![]+[])+(!+[]+(!![])+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![])+(!+[]+(!![])+!![])+(!+[]+(!![])+!![]+!![]+!![])+(!+[]+(!![])+!![]+!![]+!![]+!![]+!![])+(!+[]+(!![])-[])+(!+[]-(!![]))+(!+[]+(!![])+!![]+!![]+!![]+!! GSK has capitalised on its strengths and available opportunities over the years and has successfully minimized weaknesses and eliminated threats. GlaxoSmithKline plc (GSK.L) has a consensus target price of GBX 1,799.56, suggesting a potential upside of 37.70%. Cookson, S. (2017) Demands of disease drive vaccine science. SWOT Analysis of McCafe AstraZeneca PLC (AZN.L) pays an annual dividend of GBX 216 per share and has a dividend yield of 2.8%. We've received widespread press coverage since 2003, Your BusinessTeacher.org purchase is secure and we're rated 4.4/5 on reviews.co.uk. GlaxoSmithKline plc (GSK.L) has a consensus target price of GBX 1,799.56, suggesting a potential upside of 37.70%. Ordered by how many other websites link to them, which can be used to evaluate a site's reputation on the internet. We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation. 1) United Airlines has one of the largest fleets in the country which serves many destinations. ECO Animal Health Group plc (EAH.L) (LON:EAH) and GlaxoSmithKline plc (GSK.L) (LON:GSK) are both medical companies, but which is the better business? Alexa's competitive analysis tools help you identify competitor strengths and weaknesses you can leverage to get the edge. GSK has used foresight and planning to position them for success in the long term. StrengthsWeakness Strategic Alliances in biotechnology and pharmaceuticals. Ability to cut down on costs. [online] Available at: http://tools.morningstar.co.uk/t92wz0sj7c/stockreport/default.aspx?SecurityToken=0P00007OD0]3]0]E0WWE$$ALL [Accessed July 29, 2012]. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. GlaxoSmithKline plc (GSK.L) (LON:GSK) and AstraZeneca PLC (AZN.L) (LON:AZN) are both large-cap medical companies, but which is the better business? An estimate of how frequently this keyword is searched across all search engines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o plagiarism, guaranteed! This is a summary of recent recommendations and price targets for GlaxoSmithKline plc (GSK.L) and AstraZeneca PLC (AZN.L), as provided by MarketBeat. all social, Start free trial for (Adapted from- Annual Report: GlaxoSmithKline Plc. Given GlaxoSmithKline plc (GSK.L)'s higher possible upside, analysts clearly believe GlaxoSmithKline plc (GSK.L) is more favorable than Vectura Group plc (VEC.L). Various sorts of unprecedented challenges are faced by the industry. Audience overlap score is calculated from an analysis of common visitors and/or search keywords. There is a constant increase of pressure from healthcare providers, regulatory issues and patent expiries. Potential to deliver strong growth by R&D team. The re-organization of GSK’s R&D department has contributed a growth of new products up to 36% and 7% in pharmaceutical sales.